Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

  • By

  • Alex E. R. Powers

  • Gretchen Davis

  • Deshae Jenkins

  • Alicia Youssef

  • William Manning

  • Jason D. Wright

  • Nancy L. Keating

  • Amy Bregar

  • Alejandro Rauh-Hain

  • Alexander Melamed

  • September 17, 2026

Share

Clinical Scorecard: Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

At a Glance

Category

Detail

Condition

Stage IIIC or IV epithelial ovarian cancer

Study Design

Retrospective cohort study using the National Cancer Database to assess treatment patterns and survival outcomes from 2004 through 2015

Treatments Compared

Neoadjuvant chemotherapy (NACT) followed by interval surgery versus primary debulking surgery (PDS)

Study Population

Patients diagnosed with stage IIIC or IV epithelial ovarian cancer from January 1, 2004, through December 31, 2015

Key Findings

NACT was associated with similar overall and progression-free survival compared with PDS; greater NACT use was associated with lower early mortality but not with long-term survival probability

Key Highlights

  • NACT shows similar overall survival and progression-free survival compared to PDS.

  • Higher NACT utilization is associated with lower early mortality.

  • No association found between NACT adoption and long-term survival probability.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of advanced-stage epithelial ovarian cancer should be confirmed through imaging and histopathology.

Management

  • Consider PDS when complete or optimal cytoreduction is feasible.

Monitoring & Follow-up

  • Monitor for perioperative morbidity and long-term survival outcomes.

Risks

  • Preoperative chemotherapy may select for resistant clones, potentially impairing long-term outcomes.

Patient & Prescribing Data

Patients diagnosed with stage IIIC or IV epithelial ovarian cancer from January 1, 2004, through December 31, 2015.

NACT use increased among high-use programs, with no compromise in median overall survival.

Clinical Best Practices

  • Utilize comparative effectiveness research methods to evaluate treatment outcomes.

  • Adhere to national guidelines favoring PDS when feasible.

Related Resources & Content

  • National Cancer Database

  • ISPOR Guidelines

Original Source(s)

Related Content